Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Q3 2025 value amounting to $131.2 million.

  • Catalyst Pharmaceuticals' Total Non-Current Liabilities rose 2115.92% to $131.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.2 million, marking a year-over-year increase of 2115.92%. This contributed to the annual value of $123.5 million for FY2024, which is 5578.86% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $131.2 million for Q3 2025, which was up 2115.92% from $115.6 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Total Non-Current Liabilities registered a high of $131.2 million during Q3 2025, and its lowest value of $31.0 million during Q4 2021.
  • Its 5-year average for Total Non-Current Liabilities is $83.4 million, with a median of $81.0 million in 2023.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 9751.59% in 2022, then soared by 2115.92% in 2025.
  • Catalyst Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $31.0 million in 2021, then surged by 97.52% to $61.1 million in 2022, then rose by 29.61% to $79.3 million in 2023, then soared by 55.79% to $123.5 million in 2024, then grew by 6.26% to $131.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $131.2 million for Q3 2025, versus $115.6 million for Q2 2025 and $114.3 million for Q1 2025.